592 related articles for article (PubMed ID: 15291906)
21. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis.
Williams A; Henzgen M; Rajakulasingam K
Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):123-6. PubMed ID: 17523386
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
23. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
24. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
[TBL] [Abstract][Full Text] [Related]
25. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
27. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Jan; 64(1):179-86. PubMed ID: 19076534
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
[TBL] [Abstract][Full Text] [Related]
30. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
[TBL] [Abstract][Full Text] [Related]
32. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
33. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
[TBL] [Abstract][Full Text] [Related]
34. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
[TBL] [Abstract][Full Text] [Related]
36. Allergen-specific immunotherapy with recombinant grass pollen allergens.
Jutel M; Jaeger L; Suck R; Meyer H; Fiebig H; Cromwell O
J Allergy Clin Immunol; 2005 Sep; 116(3):608-13. PubMed ID: 16159631
[TBL] [Abstract][Full Text] [Related]
37. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
[TBL] [Abstract][Full Text] [Related]
39. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial.
Bager P; Arnved J; Rønborg S; Wohlfahrt J; Poulsen LK; Westergaard T; Petersen HW; Kristensen B; Thamsborg S; Roepstorff A; Kapel C; Melbye M
J Allergy Clin Immunol; 2010 Jan; 125(1):123-30.e1-3. PubMed ID: 19800680
[TBL] [Abstract][Full Text] [Related]
40. Long-term clinical efficacy of grass-pollen immunotherapy.
Durham SR; Walker SM; Varga EM; Jacobson MR; O'Brien F; Noble W; Till SJ; Hamid QA; Nouri-Aria KT
N Engl J Med; 1999 Aug; 341(7):468-75. PubMed ID: 10441602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
